Yubing Xie

Prof. Dr. Yubing Xie

College of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY 12203, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2013 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
KTKaren Y. Torrejon
Karen Y. Torrejon
DPDennis Pu
Dennis Pu
MBMagnus Bergkvist
Magnus Bergkvist
JDJohn Danias
John Danias
Susan T. SharfsteinSusan T. Sharfstein
Susan T. Sharfstein
Yubing XieYubing Xie
Yubing Xie

7 December 2016 in Scientific Reports
Verified
Journal Article
Open access
KTKaren Y. Torrejon
Karen Y. Torrejon
EPEllen L. Papke
Ellen L. Papke
JHJustin R. Halman
Justin R. Halman
MBMagnus Bergkvist
Magnus Bergkvist
JDJohn Danias
John Danias
Yubing XieYubing Xie
Yubing Xie
Members of the transforming growth factor beta (TGFβ) cytokine family have long been associated with affecting several cellular functions, including cell proliferation, differentiation and extracellular matrix (ECM) turnover. Of particular interest to this work, TGFβ2 has been linked to most types of glaucomas as a potential fibrotic agent that can cause elevation of intraocular pressure (IOP). Given that the trabecular meshwork (TM) provides most of aqueous humor outflow resistance in the eye, an in vitro bioengineered human TM (HTM) model has been created and validated by analyzing effects of TGFβ2 on transcellular pressure changes and outflow facility. These changes were correlated with several biological alterations induced by this cytokine, including ECM production and overexpression of HTM-marker myocillin. Furthermore, this TM model has been used to extend current knowledge of gene expression of cytokines involved in TGFβ-induced ECM turnover over time. In particular, the ability for a ROCK-inhibitor to diminish the effect of TGFβ on TM was demonstrated. This work supports the notion that anti-fibrotic activities of ROCK-inhibitors could counteract the elevation of IOP and increased strain observed in glaucomatous TM.

28 November 2015 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
KTKaren Y. Torrejon
Karen Y. Torrejon
EPEllen L. Papke
Ellen L. Papke
JHJustin R. Halman
Justin R. Halman
JSJudith Stolwijk
Judith Stolwijk
CDCula N. Dautriche
Cula N. Dautriche
Yubing XieYubing Xie
Yubing Xie

21 September 2015 in Journal of Functional Biomaterials
Verified
Journal Article
Open access
PDF file
CDCula Dautriche
Cula Dautriche
YTYangzi Tian
Yangzi Tian
Yubing XieYubing Xie
Yubing Xie
Susan T. SharfsteinSusan T. Sharfstein
Susan T. Sharfstein
Among ocular pathologies, glaucoma is the second leading cause of progressive vision loss, expected to affect 80 million people worldwide by 2020. A primary cause of glaucoma appears to be damage to the conventional outflow tract. Conventional outflow tissues, a composite of the trabecular meshwork and the Schlemm’s canal, regulate and maintain homeostatic responses to intraocular pressure. In glaucoma, filtration of aqueous humor into the Schlemm’s canal is hindered, leading to an increase in intraocular pressure and subsequent damage to the optic nerve, with progressive vision loss. The Schlemm’s canal encompasses a unique endothelium. Recent advances in culturing and manipulating Schlemm’s canal cells have elucidated several aspects of their physiology, including ultrastructure, cell-specific marker expression, and biomechanical properties. This review highlights these advances and discusses implications for engineering a 3D, biomimetic, in vitro model of the Schlemm’s canal endothelium to further advance glaucoma research, including drug testing and gene therapy screening.

13 December 2012 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
MZMichael R. Zonca
Michael R. Zonca
PYPhilip Sungho Yune
Philip Sungho Yune
CHCaryn L. Heldt
Caryn L. Heldt
GBGeorges Belfort
Georges Belfort
Yubing XieYubing Xie
Yubing Xie

1 November 2015 in Biotechnology Advances
Verified
Journal Article
Closed access
AUAndrea M. Unser
Andrea M. Unser
YTYangzi Tian
Yangzi Tian
Yubing XieYubing Xie
Yubing Xie